Charles River Laboratories Inte with ticker code (CRL) have now 11 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 440 and 350 and has a mean target at 398.55. Given that the stocks previous close was at 291.63 this indicates there is a potential upside of 36.7%. The 50 day MA is 342.83 and the 200 moving average now moves to 378.74. The market cap for the company is $14,823m. Find out more information at: https://www.criver.com
The potential market cap would be $20,258m based on the market concensus.
Charles River Laboratories International, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
